天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Polypeptide>Bivalirudin
Bivalirudin
  • Bivalirudin
  • Bivalirudin
  • Bivalirudin
  • Bivalirudin
  • Bivalirudin

Bivalirudin NEW

Price Get Latest Price
Package 1kg
Min. Order: 1kg
Supply Ability: 10000kg
Update Time: 2024-04-16

Product Details

Product Name: Bivalirudin CAS No.: 128270-60-0
EC-No.: 274-570-6 Min. Order: 1kg
Purity: 99% Supply Ability: 10000kg
Release date: 2024/04/16

Manufacturer Provide Pharmaceutical Grade CAS 128270-60-0 Bivalirudin Purity Peptide Bivalirudin Powder


Article illustration

Introduction

Product Name:   Bivalirudin

Other Name :BIVALIRUDIN TRIFLUOROACETATE

CAS NO: 128270-60-0

Purity: 99%min
Appearance
:White Powder

Molecular formula: C98H138N24O33

Molecular weight :2180.29

Density :1.52±0.1 g/cm3(Predicted)


Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.


Application 

1. It can significantly reduce the incidence of bleeding in elective PCI patients. The total clinical outcome risk fell 14%.
2. It does not cause antibody-mediated thrombocytopenia.
3. Reversibly bind with thrombin. Short half-life. Hard to develop ischemic and hemorrhagic complications.
4. It is not mainly excreted through the kidneys and can be safely used in patients with renal impairment.

Article illustration


Company Profile Introduction

Shaanxi TNJONE Pharmaceutical Co., Ltd supplies more than 2,000 kinds of products, covering the whole field of health industry, including human APIs, veterinary APIs, food additives, natural nutrition ingredients, feed additives, cosmetic additives, intermediates etc. With global sourcing advantages, the group is fully capable of meeting the one-stop sourcing needs of global customers. Today, Shaanxi TNJONE Pharmaceutical Co., Ltd.'s marketing network has spread over more than 100 countries and regions on five continents, providing professional service for global customers.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/1Box
VIP1Y
American HealthyMorph LLC
2024-12-26
$37.00/5mg
VIP5Y
TargetMol Chemicals Inc.
2024-11-19
$10.00/1KG
VIP6Y
Hebei Weibang Biotechnology Co., Ltd
2024-11-19
$0.00/1BOX
VIP1Y
Shandong Huizhihan Supply Chain Co., Ltd
2024-11-12
$0.00/1Box
VIP1Y
Shanghai Affida new material science and technology center
2024-04-12
$28.00/1box
VIP1Y
Shanghai Getian Industrial Co., LTD
2024-04-11
$30.00/1box
VIP1Y
hebei hongtan Biotechnology Co., Ltd
2024-03-20
$10.00/1kg
Nantong Guangyuan Chemicl Co,Ltd
2023-11-15
$60.00/1kg
VIP2Y
Zibo Hangyu Biotechnology Development Co., Ltd
2023-10-27
$30.00/1g
Shanghai Yunao International Trade Co., Ltd
2023-10-11

Shaanxi TNJONE Pharmaceutical Co., Ltd

1YR ChinaChina
  • Since: 2019-05-23
  • Address: No. 4C-11-A392, Financial Port, Northwest corner of Fengjing Avenue and Fengxin Road, Fengdong New C
INQUIRY